Janku Filip 4

What Happened

• Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics (GLUE), exercised options to acquire 36,000 shares (6,000 on 6/23 and 30,000 on 6/24) at $7.56 per share (cost = $272,160). He also sold 41,845 shares in open-market transactions (11,845 on 6/23 and 30,000 on 6/24) for aggregate proceeds of approximately $882,203. Sales were done under a Rule 10b5-1 trading plan.

Key Details

• Transaction dates and prices:
  • 2026-06-23: Exercised 6,000 shares @ $7.56 (acq. $45,360); sold 11,845 shares @ weighted avg $20.22 (proceeds $239,522). Sales prices ranged $19.95–$20.50 per F2.
  • 2026-06-24: Exercised 30,000 shares @ $7.56 (acq. $226,800); sold 30,000 shares @ weighted avg $21.42 (proceeds $642,681). Sales prices ranged $21.30–$21.59 per F3.
  • Two additional derivative-line entries show disposals at $0.00 (6,000 and 30,000) — these reflect the conversion/settlement of derivative instruments upon exercise rather than market sales.
• Total cash paid to exercise options: $272,160. Total cash received from open-market sales: ~$882,203.
• Footnotes: F1 — sales were effected under a 10b5-1 plan adopted March 4, 2026; F4 — the exercised options were fully vested and exercisable.
• Filing: Form 4 filed 2026-06-25 for transactions on 6/23–6/24 (appears timely; no late filing indicated).
• Shares owned after the transactions: not specified in the provided summary.

Context

• This was an option exercise combined with open-market sales. The exercised shares appear to have been at least partly sold; total shares sold (41,845) exceed the 36,000 newly acquired, so some sold may have come from prior holdings. Exercises of vested options are routine for insiders; open-market sales under a prearranged 10b5-1 plan are typically automated, not necessarily a directional signal about company prospects.
• If you want the exact breakdown of how many shares sold at each price within the reported ranges, the filer notes they will provide that on request to the company, shareholders, or the SEC.